Xencor reports promising kidney cancer drug results, plans late-stage trial

What happened: Xencor (XNCR) reported early-stage results for its kidney cancer drug XmAb819, with tumors shrinking in nearly half of patients at the highest dose tested, and outlined plans to seek accelerated FDA approval and start a larger trial by the end of 2027. Key numbers: Among 11 Why it matters: The results suggest XmAb819 could become a new option for patients whose kidney cancer stopped responding to existing therapies and support plans toward regulatory approval, though the small patient count and lack of a randomized comparison group make it too early to judge superiority. Market: -2.5% today ($25.18), +68.8% YTD, 1.1x vol — as of 22:46 UTC

Xencor (XNCR) reported early-stage results for its kidney cancer drug XmAb819, with tumors shrinking in nearly half of patients at the highest dose tested, and outlined plans to seek accelerated FDA approval and start a larger trial by the end of 2027.

The results suggest XmAb819 could become a new option for patients whose kidney cancer stopped responding to existing therapies and support plans toward regulatory approval, though the small patient count and lack of a randomized comparison group make it too early to judge superiority. Market: -2.5% today ($25.18), +68.8% YTD, 1.1x vol — as of 22:46 UTC